AAPL329.89-3.19 (-0.96%) ▼|ABBV262.61+0.84 (+0.32%) ▲|ABT102.00-1.09 (-1.06%) ▼|ACN195.83+0.83 (+0.43%) ▲|ADBE260.77-4.83 (-1.82%) ▼|AMAT419.81-4.40 (-1.04%) ▼|AMD503.78+10.37 (+2.10%) ▲|AMGN377.98-3.53 (-0.92%) ▼|AMT178.43+1.49 (+0.84%) ▲|AMZN249.01-4.53 (-1.79%) ▼|AVGO340.65-4.07 (-1.18%) ▼|AXP323.14-4.64 (-1.42%) ▼|BA209.13-1.14 (-0.54%) ▼|BAC59.12-0.36 (-0.60%) ▼|BKNG170.94-4.41 (-2.52%) ▼|BLK1,056.00-9.60 (-0.90%) ▼|BMY63.91-0.19 (-0.30%) ▼|BNY153.25-4.41 (-2.80%) ▼|BRK-B516.19+1.24 (+0.24%) ▲|C135.20-0.98 (-0.72%) ▼|CAT781.96-2.04 (-0.26%) ▼|CL87.09-0.80 (-0.91%) ▼|CMCSA24.61-0.28 (-1.11%) ▼|COF204.28-2.40 (-1.16%) ▼|COP140.20+3.53 (+2.58%) ▲|COST908.78-10.13 (-1.10%) ▼|CRM259.29-0.14 (-0.05%) ▼|CSCO110.80+0.74 (+0.67%) ▲|CVS94.42-1.13 (-1.18%) ▼|CVX216.31+4.14 (+1.95%) ▲|DE686.30+4.84 (+0.71%) ▲|DHR208.01+4.76 (+2.34%) ▲|DIS107.63-0.96 (-0.88%) ▼|DUK118.27-0.75 (-0.63%) ▼|EMR146.25-2.05 (-1.38%) ▼|FDX308.33-4.24 (-1.36%) ▼|GD357.50+0.69 (+0.19%) ▲|GE308.25-9.31 (-2.93%) ▼|GEV877.69+2.93 (+0.33%) ▲|GILD145.72+0.13 (+0.09%) ▲|GM85.61-1.55 (-1.78%) ▼|GOOG339.92-5.80 (-1.68%) ▼|GOOGL343.45-5.94 (-1.70%) ▼|GS960.99-27.46 (-2.78%) ▼|HD306.13-4.74 (-1.52%) ▼|HON201.19-0.19 (-0.09%) ▼|IBM248.70-0.39 (-0.16%) ▼|INTC98.30+1.11 (+1.14%) ▲|INTU331.73-7.42 (-2.19%) ▼|ISRG375.45-2.49 (-0.66%) ▼|JNJ264.91-1.41 (-0.53%) ▼|JPM344.99-5.15 (-1.47%) ▼|KO88.59-0.23 (-0.26%) ▼|LIN461.38-3.04 (-0.65%) ▼|LLY1,146.16+7.88 (+0.69%) ▲|LMT530.40+1.02 (+0.19%) ▲|LOW195.10-3.07 (-1.55%) ▼|LRCX267.88-5.61 (-2.05%) ▼|MA572.61-1.81 (-0.32%) ▼|MCD256.17-1.32 (-0.51%) ▼|MDLZ62.17-0.22 (-0.35%) ▼|MDT94.01+0.21 (+0.22%) ▲|META666.22+0.62 (+0.09%) ▲|MMM164.56+2.54 (+1.57%) ▲|MO70.18+0.68 (+0.97%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS201.33-5.25 (-2.54%) ▼|MSFT499.27-6.14 (-1.21%) ▼|MU927.13+3.10 (+0.33%) ▲|NEE81.53-0.10 (-0.12%) ▼|NFLX78.00-2.33 (-2.89%) ▼|NKE36.40-0.65 (-1.75%) ▼|NOW144.72+2.37 (+1.66%) ▲|NVDA212.27+1.31 (+0.62%) ▲|ORCL143.54-1.25 (-0.86%) ▼|PEP135.68-0.66 (-0.48%) ▼|PFE27.57-0.15 (-0.54%) ▼|PG147.13+1.00 (+0.68%) ▲|PLTR172.46-0.86 (-0.49%) ▼|PM194.60-0.26 (-0.13%) ▼|QCOM187.35+7.20 (+4.00%) ▲|RTX194.90-0.44 (-0.23%) ▼|SBUX96.63-2.45 (-2.47%) ▼|SCHW108.30+0.99 (+0.92%) ▲|SO86.35-0.65 (-0.75%) ▼|SPG203.59-1.38 (-0.67%) ▼|T26.73+0.22 (+0.81%) ▲|TMO636.55+23.40 (+3.82%) ▲|TMUS181.67-1.23 (-0.67%) ▼|TSLA360.43+1.46 (+0.41%) ▲|TXN264.38+0.96 (+0.36%) ▲|UBER71.63-1.00 (-1.38%) ▼|UNH377.72-5.84 (-1.52%) ▼|UNP284.13-0.95 (-0.33%) ▼|UPS102.25-0.21 (-0.21%) ▼|USB62.01-0.67 (-1.07%) ▼|V374.90-0.38 (-0.10%) ▼|VZ51.42+0.13 (+0.24%) ▲|WFC88.16-0.56 (-0.63%) ▼|WMT108.51-0.57 (-0.52%) ▼|XOM169.13+4.05 (+2.45%) ▲|AAPL329.89-3.19 (-0.96%) ▼|ABBV262.61+0.84 (+0.32%) ▲|ABT102.00-1.09 (-1.06%) ▼|ACN195.83+0.83 (+0.43%) ▲|ADBE260.77-4.83 (-1.82%) ▼|AMAT419.81-4.40 (-1.04%) ▼|AMD503.78+10.37 (+2.10%) ▲|AMGN377.98-3.53 (-0.92%) ▼|AMT178.43+1.49 (+0.84%) ▲|AMZN249.01-4.53 (-1.79%) ▼|AVGO340.65-4.07 (-1.18%) ▼|AXP323.14-4.64 (-1.42%) ▼|BA209.13-1.14 (-0.54%) ▼|BAC59.12-0.36 (-0.60%) ▼|BKNG170.94-4.41 (-2.52%) ▼|BLK1,056.00-9.60 (-0.90%) ▼|BMY63.91-0.19 (-0.30%) ▼|BNY153.25-4.41 (-2.80%) ▼|BRK-B516.19+1.24 (+0.24%) ▲|C135.20-0.98 (-0.72%) ▼|CAT781.96-2.04 (-0.26%) ▼|CL87.09-0.80 (-0.91%) ▼|CMCSA24.61-0.28 (-1.11%) ▼|COF204.28-2.40 (-1.16%) ▼|COP140.20+3.53 (+2.58%) ▲|COST908.78-10.13 (-1.10%) ▼|CRM259.29-0.14 (-0.05%) ▼|CSCO110.80+0.74 (+0.67%) ▲|CVS94.42-1.13 (-1.18%) ▼|CVX216.31+4.14 (+1.95%) ▲|DE686.30+4.84 (+0.71%) ▲|DHR208.01+4.76 (+2.34%) ▲|DIS107.63-0.96 (-0.88%) ▼|DUK118.27-0.75 (-0.63%) ▼|EMR146.25-2.05 (-1.38%) ▼|FDX308.33-4.24 (-1.36%) ▼|GD357.50+0.69 (+0.19%) ▲|GE308.25-9.31 (-2.93%) ▼|GEV877.69+2.93 (+0.33%) ▲|GILD145.72+0.13 (+0.09%) ▲|GM85.61-1.55 (-1.78%) ▼|GOOG339.92-5.80 (-1.68%) ▼|GOOGL343.45-5.94 (-1.70%) ▼|GS960.99-27.46 (-2.78%) ▼|HD306.13-4.74 (-1.52%) ▼|HON201.19-0.19 (-0.09%) ▼|IBM248.70-0.39 (-0.16%) ▼|INTC98.30+1.11 (+1.14%) ▲|INTU331.73-7.42 (-2.19%) ▼|ISRG375.45-2.49 (-0.66%) ▼|JNJ264.91-1.41 (-0.53%) ▼|JPM344.99-5.15 (-1.47%) ▼|KO88.59-0.23 (-0.26%) ▼|LIN461.38-3.04 (-0.65%) ▼|LLY1,146.16+7.88 (+0.69%) ▲|LMT530.40+1.02 (+0.19%) ▲|LOW195.10-3.07 (-1.55%) ▼|LRCX267.88-5.61 (-2.05%) ▼|MA572.61-1.81 (-0.32%) ▼|MCD256.17-1.32 (-0.51%) ▼|MDLZ62.17-0.22 (-0.35%) ▼|MDT94.01+0.21 (+0.22%) ▲|META666.22+0.62 (+0.09%) ▲|MMM164.56+2.54 (+1.57%) ▲|MO70.18+0.68 (+0.97%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS201.33-5.25 (-2.54%) ▼|MSFT499.27-6.14 (-1.21%) ▼|MU927.13+3.10 (+0.33%) ▲|NEE81.53-0.10 (-0.12%) ▼|NFLX78.00-2.33 (-2.89%) ▼|NKE36.40-0.65 (-1.75%) ▼|NOW144.72+2.37 (+1.66%) ▲|NVDA212.27+1.31 (+0.62%) ▲|ORCL143.54-1.25 (-0.86%) ▼|PEP135.68-0.66 (-0.48%) ▼|PFE27.57-0.15 (-0.54%) ▼|PG147.13+1.00 (+0.68%) ▲|PLTR172.46-0.86 (-0.49%) ▼|PM194.60-0.26 (-0.13%) ▼|QCOM187.35+7.20 (+4.00%) ▲|RTX194.90-0.44 (-0.23%) ▼|SBUX96.63-2.45 (-2.47%) ▼|SCHW108.30+0.99 (+0.92%) ▲|SO86.35-0.65 (-0.75%) ▼|SPG203.59-1.38 (-0.67%) ▼|T26.73+0.22 (+0.81%) ▲|TMO636.55+23.40 (+3.82%) ▲|TMUS181.67-1.23 (-0.67%) ▼|TSLA360.43+1.46 (+0.41%) ▲|TXN264.38+0.96 (+0.36%) ▲|UBER71.63-1.00 (-1.38%) ▼|UNH377.72-5.84 (-1.52%) ▼|UNP284.13-0.95 (-0.33%) ▼|UPS102.25-0.21 (-0.21%) ▼|USB62.01-0.67 (-1.07%) ▼|V374.90-0.38 (-0.10%) ▼|VZ51.42+0.13 (+0.24%) ▲|WFC88.16-0.56 (-0.63%) ▼|WMT108.51-0.57 (-0.52%) ▼|XOM169.13+4.05 (+2.45%) ▲|
20.3 C
New York
Tuesday, September 15, 2026

Tag: management

newssourceFORcompanyinformationcontent1releasesmarket

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

IIM Udaipur Concludes Executive Education Training Program for PM SHRI School Principals in Collaboration with RSSP Jaipur

UDAIPUR, India, June 21, 2025 /PRNewswire/ -- Indian Institute of Management Udaipur (IIM Udaipur), in collaboration with the Rajasthan School Shiksha Parishad (RSSP), Jaipur,...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

MolecuLight Showcases Innovative Multimodal Imaging with Thermal Capabilities at St. Louis Wound & Vascular Symposium

PITTSBURGH, June 21, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, is proud to showcase its presence...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

TEAMSTERS NURSES AT COREWELL TO RALLY AGAINST EMPLOYERS’ ATTACKS

Nurses to Rally Outside Detroit Ahead of Contract Negotiations DETROIT, June 21, 2025 /PRNewswire/ -- Nurses at Corewell Health East, represented by Teamsters Local 2024, will...

High Arctic Announces Annual General and Special Meeting Results

High Arctic Announces Annual General and Special Meeting Results

The China Fund, Inc. Announces Board Approval of Plan of Liquidation

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- The China Fund, Inc. (NYSE: CHN) (the “Fund”) announced today that its Board of Directors (the “Board”) has approved a plan of liquidation and dissolution (the “Plan”) for the Fund. The Plan will be submitted to Fund stockholders for approval at a Special Meeting. The date of the Special Meeting and more detailed information about the proposed liquidation and Plan will be set forth in a proxy statement to be mailed to the Fund’s stockholders in the near future. The Board recommends that the Fund’s stockholders vote for the liquidation of the Fund at the Special Meeting.

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company 
Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsManagement

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers